Skin Cancer Imaging with MoleMate Featured At Annual Shareholder's Meeting and Upcoming American Academy of Dermatology Meeting in San Diego

About this update from Medx Health Corp.

[{"type":"text","content":"\n\n\n\n\n\nPresident & CEO, Steve Guillen outlines how the technology in MoleMate\n is transforming the Company through new market introductions\n\n\nMISSISSAUGA, ON, March 15, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy\n and light imaging systems, announced today that their Annual\n Shareholders' Meeting was held on March 13, 2012, at 4 p.m. at the\n National Club in Toronto, where the President and CEO, Steve Guillen\n reviewed the impact that SIAscopy has already made on the Company and\n highlighted the expected opportunities in the future.\n\n\nAt the meeting of shareholders, Mr. Guillen expanded upon and the\n following regarding MoleMate:\n\n\nTransition to a technology platform company as a result of the\n acquisition of SIAscopy in June 2011;\n\n\nOn-line imaging services utilizing 'cloud' technology, which allows the\n company to move from simply a device company to a device and services\n company; \"now we have the razor and razor blade model allowing us to\n capture recurring revenues,\" said Mr. Guillen;\n\n\nAcceleration of new market entries: skin cancer, burns, wound care; and\n provided additional information on diabetic foot ulcers and bed sores\n wounds which comprise a multi-million dollar opportunity in the near\n future;\n\n\nKey R&D partners in Proctor & Gamble and Unilever were acknowledged;\n\n\nDiscussed the improved accuracy showing a marked improvement in the\n physician's ability to identify melanoma as well as identify benign\n moles, leading to earlier diagnosis when the cure rate is the highest,\n as well as resulting in fewer benign moles referred or removed;\n\n\nAddition of Mole Mapping in 2012; which should continue to differentiate\n MoleMate and SIMSYS from other devices entering the market that are\n more costly to acquire and use, and do not offer the range of feedback\n on all moles, including stored images to track changes, and in some\n cases are limited to dermatologists only;\n\n\nBroad worldwide patent portfolio;  includes 9 core patents that have\n been granted throughout the world, and cover a range of methods and\n devices related to the use of light in imaging the skin;\n\n\nStrong sales in Q4, 2011, led by MoleMate; best quarter in over three\n (3) years; and mentioned that the year-end nu...

More updates from Medx Health Corp.